CorMedix (CRMD) Return on Capital Employed (2011 - 2026)
CorMedix (CRMD) posted Return on Capital Employed of 24.44% for Q4 2025, down 13.45% sequentially from 28.24% in Q3 2025, and up 5917.0% YoY from 0.41% in Q4 2024.
CorMedix (CRMD) Return on Capital Employed (2011 - 2026) Analysis & Trends
CorMedix has reported Return on Capital Employed for 13 years, with the latest figure at 24.44% in Q4 2025.
- Quarterly Return on Capital Employed rose 5917.0% year-over-year to 24.44% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 24.44% (up 5917.0% YoY) and the FY2025 annual result came in at 50.34%, up 8391.0% from the prior year.
- Return on Capital Employed fell to 24.44% in Q4 2025 per CRMD's latest filing, from 28.24% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.12% in Q2 2025 and troughed at 112.32% in Q2 2024.
- A 5-year average of 43.29% and a median of 48.43% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 4101 bps in 2024, then soared 14143 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 44.05% in 2021, then fell by 25 bps to 54.93% in 2022, then dropped by 18 bps to 64.98% in 2023, then jumped by 47 bps to 34.73% in 2024, then jumped by 170 bps to 24.44% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 24.44%, 28.24%, and 29.12% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 25.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.52% |
| Dec 31, 2025 | 24.44% |
| Sep 30, 2025 | 28.24% |
| Jun 30, 2025 | 29.12% |
| Mar 31, 2025 | 14.50% |
| Dec 31, 2024 | -34.73% |
| Sep 30, 2024 | -103.63% |
| Jun 30, 2024 | -112.32% |
| Mar 31, 2024 | -83.42% |
| Dec 31, 2023 | -64.98% |
| Sep 30, 2023 | -62.62% |
| Jun 30, 2023 | -75.22% |
| Mar 31, 2023 | -61.84% |
| Dec 31, 2022 | -54.93% |
| Sep 30, 2022 | -50.15% |
| Jun 30, 2022 | -51.77% |
| Mar 31, 2022 | -46.71% |
| Dec 31, 2021 | -44.05% |
| Sep 30, 2021 | -38.05% |
| Jun 30, 2021 | -32.46% |